Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sinovac Files for Approval of its EV71 Vaccine

publication date: May 30, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinovac Biotech reported the Beijing Drug Administration has accepted the company's filing of a New Drug Application for its novel enterovirus 71 vaccine. The vaccine, which completed its Phase III trial in March, achieved a 95% efficacy against Hand, Foot and Mouth Disease. Yesterday, Beijing Vigoo Biological, a China National Biotec unit, published data in The Lancet, revealing its EV71 vaccine had a near-identical 90% efficacy. More details....

Stock Symbol: (NSDQ: SVA)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners